Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A pair of oncology program presentations
January 2016
SHARING OPTIONS:

LEXINGTON, Mass.—Biotechnology company Curis Inc. recently announced that its collaborator Aurigene shared preclinical data from two programs AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Those programs included CA-170, a first-in-class oral, small-molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA), and the interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor program. Curis exercised options to license the programs under a collaboration agreement with Aurigene struck earlier this year.
 
“The collective in-vitro and animal model data are very compelling and strongly support testing of CA-170 in human clinical trials in multiple cancers,” said Dr. Ali Fattaey, Curis’ president and CEO. “We are working with Aurigene to complete the IND enabling studies for CA-170 and initiate clinical studies in the first half of 2016.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.